The receival of Ce mark is expected to expand the market opportunities for the VerifyNow System in both surgical and interventional cardiology patient populations, according to the company.

The company is planning to release the VerifyNow II product line in Europe starting early in 2013.

Accumetrics president and CEO Timothy Still said as the clinical role of platelet reactivity testing continues to gain traction in the interventional cardiology marketplace, the company is pleased to see additional clinical specialties, such as surgery and interventional neuroradiology, demonstrate an increased need for platelet reactivity testing as well.

"As the leader in platelet reactivity testing, we remain focused on producing high quality diagnostic tests that provide critical information to physicians to help improve the quality of care for patients on these life-saving antiplatelet agents," Still added.

The VerifyNow System is presently used in more than 800 facilities in the US and over 70 countries across the globe where antiplatelet medications are prescribed to reduce the occurrence of future thrombotic events such as heart attack and stroke.